# Serena Ricciardi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/serena-ricciardi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,649 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 21 |
| i10-index | 31 |
| Last Known Institution | Nini Hospital |
| OpenAlex ID | https://openalex.org/A5065057377 |
| ORCID iD | 0000-0001-5401-4836 |
| Works | 80 |

## Researcher papers

- [Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies](https://scholariq.org/papers/bone-and-brain-metastasis-in-lung-cancer-recent-advances-in-therapeutic/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)
- [Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation](https://scholariq.org/papers/baseline-bmi-and-bmi-variation-during-first-line-pembrolizumab-in-nsclc-patients/)
- [Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%](https://scholariq.org/papers/clinicopathologic-correlates-of-first-line-pembrolizumab-effectiveness-in/)
- [Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes](https://scholariq.org/papers/immune-related-adverse-events-of-pembrolizumab-in-a-large-real-world-cohort-of/)
- [Toxicity of Targeted Therapy in Non–Small-Cell Lung Cancer Management](https://scholariq.org/papers/toxicity-of-targeted-therapy-in-non-small-cell-lung-cancer-management/)
- [Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer](https://scholariq.org/papers/real-life-results-from-the-overall-population-and-key-subgroups-within-the/)
- [Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial](https://scholariq.org/papers/addition-of-bevacizumab-to-erlotinib-as-first-line-treatment-of-patients-with/)
- [Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples](https://scholariq.org/papers/correlation-between-cytidine-deaminase-genotype-and-gemcitabine-deamination-in/)
- [Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours](https://scholariq.org/papers/characteristics-and-outcomes-of-immunotherapy-related-liver-injury-in-patients/)
- [Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients](https://scholariq.org/papers/intrapatient-molecular-and-histologic-heterogeneity-after-first-generation-or/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Nini Hospital](https://scholariq.org/institutions/nini-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.